3 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
Follow vupanorsen: new trials by email Literature Review of vupanorsen trials Research Report on vupanorsen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70) Vupanorsen, Placebo - Dyslipidemias, Hyperlipidemias | Phase 2 | Completed | Pfizer | 286 | 2020-09-28 | 2022-10-04 |
| Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease Placebo, ISIS 703802 40 mg, ISIS 703802 80 mg - NAFLD, Diabetes Mellitus, Type 2 | Phase 2 | Completed | Akcea Therapeutics | 105 | 2017-12-21 | 2021-02-01 |
| Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS) AKCEA-ANGPTL3-LRx - Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency | Phase 2 | Completed | Akcea Therapeutics | 3 | 2017-12-21 | 2021-01-07 |
Metabolic Diseases (3) · Dyslipidemias (2) · Hyperlipidemias (2) · Hyperlipoproteinemias (2) · Lipid Metabolism Disorders (2) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Digestive System Diseases (1) · Endocrine System Diseases (1) · Familial hyperchylomicronemia syndrome (1) · Fatty Liver (1) · Genetic Diseases, Inborn (1) · Glucose Metabolism Disorders (1) · Hyperlipoproteinemia Type I (1) · Hypertriglyceridemia (1)
Akcea Therapeutics (2) · Pfizer (1)
Canada (3) · United States (2) · Poland (1)